ABSTRACT
Objective To investigate the clinical efficacy of letrozole and clomiphene in the treatment of polycystic ovary syndrome in patients with ovulatory disorder. Methods Retrospective analysis of 480 cases diagnosed as polycystic ovary syndrome caused by ovarian infertility in patients with clinical diagnosis and treatment of information from January 2015 to January 2017, in which the treatment of cimetidine urinary hormone therapy as the control group (n=240), using letrozole urinary hormone therapy for the treatment group (n=240). The serum levels of sex hormones were measured before and after treatment in both groups. The endometrial thickness of patients was monitored by B-ultrasonography. Adverse reactions were recorded during treatment. Results The total effective rate was significantly higher in the treatment group than in the control group (P<0.05). The ovulation rate and pregnancy rate of the treatment group were 75.0% and 67.5% respectively, which was significantly higher than that of the control group (52.5%), 42.5% , χ2=(26.28, 30.30), P=(0.00,0.00). The levels of LH and T in the treatment group were (6.69±1.32) IU/L, (0.97±0.55) ng/mL, which was significantly lower than that in the control group (9.88±1.78) IU/L, (1.36±0.81) ng/mL. E2 in the treatment group was (44.25±10.71) pg/mL, significantly higher than that of the control group (39.35±7.69) pg/mL(P<0.05). The thickness of endometrium in the treatment group was significantly higher than that in the control group (P<0.05). No significant adverse reaction was observed during the treatment period. Conclusion Letrozole combined with urinary hormone treatment of polycystic ovary syndrome caused by ovarian disorder infertility patients with significant effect.
ABSTRACT
Objective To investigate the clinical efficacy of letrozole and clomiphene in the treatment of polycystic ovary syndrome in patients with ovulatory disorder. Methods Retrospective analysis of 480 cases diagnosed as polycystic ovary syndrome caused by ovarian infertility in patients with clinical diagnosis and treatment of information from January 2015 to January 2017, in which the treatment of cimetidine urinary hormone therapy as the control group (n=240), using letrozole urinary hormone therapy for the treatment group (n=240). The serum levels of sex hormones were measured before and after treatment in both groups. The endometrial thickness of patients was monitored by B-ultrasonography. Adverse reactions were recorded during treatment. Results The total effective rate was significantly higher in the treatment group than in the control group (P<0.05). The ovulation rate and pregnancy rate of the treatment group were 75.0% and 67.5% respectively, which was significantly higher than that of the control group (52.5%), 42.5% , χ2=(26.28, 30.30), P=(0.00,0.00). The levels of LH and T in the treatment group were (6.69±1.32) IU/L, (0.97±0.55) ng/mL, which was significantly lower than that in the control group (9.88±1.78) IU/L, (1.36±0.81) ng/mL. E2 in the treatment group was (44.25±10.71) pg/mL, significantly higher than that of the control group (39.35±7.69) pg/mL(P<0.05). The thickness of endometrium in the treatment group was significantly higher than that in the control group (P<0.05). No significant adverse reaction was observed during the treatment period. Conclusion Letrozole combined with urinary hormone treatment of polycystic ovary syndrome caused by ovarian disorder infertility patients with significant effect.